Media headlines about Tonix Pharmaceuticals (NASDAQ:TNXP) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.623794243699 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) traded up $0.15 on Friday, hitting $3.81. The stock had a trading volume of 412,313 shares, compared to its average volume of 85,231. Tonix Pharmaceuticals has a 52 week low of $2.85 and a 52 week high of $9.40. The company has a market capitalization of $28.55, a P/E ratio of -1.13 and a beta of 2.62.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.02). sell-side analysts anticipate that Tonix Pharmaceuticals will post -3.23 EPS for the current fiscal year.

A number of brokerages have recently issued reports on TNXP. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Friday, December 1st. ValuEngine downgraded Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.33.

In other Tonix Pharmaceuticals news, Director Ernest Mario sold 36,967 shares of Tonix Pharmaceuticals stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $3.51, for a total value of $129,754.17. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at $35,100. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 48,934 shares of company stock valued at $172,496. 4.00% of the stock is currently owned by corporate insiders.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.